The Prevalence of Antibodies to Adenovirus Serotype 5 in an Adult Indian Population and Implications for Adenovirus Vector Vaccines

被引:39
作者
Pilankatta, Rajendra [1 ]
Chawla, Tanu [1 ]
Khanna, Navin [1 ]
Swaminathan, Sathyamangalam [1 ]
机构
[1] Int Ctr Genet Engn & Biotechnol, Recombinant Gene Prod Grp, New Delhi 110067, India
关键词
adenovirus; adenoviral vaccine; prior adenovirus immunity; CAR; Fc receptor; NEUTRALIZING ANTIBODIES; GENE-TRANSFER; IMMUNE-RESPONSES; RHESUS-MONKEYS; CELL-LINE; REPLICATION; IMMUNOGENICITY; VIRUS; INDUCTION; INFECTION;
D O I
10.1002/jmv.21721
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In vivo gene delivery using human adenovirus serotype 5 (AdV5) vectors is being explored for vaccination purposes. The presence of anti-AdV5 antibodies in human serum arising from natural exposure to AdV5 can interfere potentially with and compromise the efficacy of rAdV5-based vaccine vectors. In this report, a collection of 114 sera from healthy adult Indian blood donors was analyzed for the presence of anti-AdV5 antibodies, using an AdV5 vector encoding the green fluorescent protein (GFP) to monitor the presence of anti-AdV5 neutralizing antibodies in human sera based on their ability to block virus entry into HeLa cells which express the Coxsackievirus- and-Adenovirus Receptor (CAR). In this assay all samples tested were positive for anti-AdV5 antibodies, with titers varying over a very wide range. It was also observed that these antibodies facilitated the uptake of the reporter AdV5 vector into the monocytic cell line U937 which does not express CAR, but expresses Fc receptors (FcRs) instead. These observations have implications for rAdV5-based vaccine development. J. Med. Virol. 82:407-414,2010. (C) 2010 Wiley-Liss, Inc.
引用
收藏
页码:407 / 414
页数:8
相关论文
共 53 条
[11]   Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: Implications and proposals for human therapy [J].
Chen, Y ;
Yu, DC ;
Charlton, D ;
Henderson, DR .
HUMAN GENE THERAPY, 2000, 11 (11) :1553-1567
[12]  
Cohen Philip, 2006, IAVI Rep, V10, P1
[13]   Functional and selective targeting of adenovirus to high-affinity fcγ receptor I-positive cells by using a bispecific hybrid adapter [J].
Ebbinghaus, C ;
Al-Jaibaji, A ;
Operschall, E ;
Schöffel, A ;
Peter, I ;
Greber, UF ;
Hemmi, S .
JOURNAL OF VIROLOGY, 2001, 75 (01) :480-489
[14]   Efficient adenoviral infection with IκBα reveals that macrophage tumor necrosis factor α production in rheumatoid arthritis is NF-κB dependent [J].
Foxwell, B ;
Browne, K ;
Bondeson, J ;
Clarke, C ;
De Martin, R ;
Brennan, F ;
Feldmann, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (14) :8211-8215
[15]  
Gahéry-Ségard H, 1998, J VIROL, V72, P2388
[16]   A simplified system for generating recombinant adenoviruses [J].
He, TC ;
Zhou, SB ;
da Costa, LT ;
Yu, J ;
Kinzler, KW ;
Vogelstein, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (05) :2509-2514
[17]  
Hitt M M, 1997, Adv Pharmacol, V40, P137, DOI 10.1016/S1054-3589(08)60140-4
[18]   Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice [J].
Hoelscher, MA ;
Garg, S ;
Bangari, DS ;
Belser, JA ;
Lu, XH ;
Stephenson, I ;
Bright, RA ;
Katz, JM ;
Mittal, SK ;
Sambhara, S .
LANCET, 2006, 367 (9509) :475-481
[19]   Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: Low seroprevalence and non-cross-reactivity with Ad5 [J].
Holterman, L ;
Vogels, R ;
van der Vlugt, R ;
Sieuwerts, M ;
Grimbergen, J ;
Kaspers, J ;
Geelen, E ;
van der Helm, E ;
Lemckert, A ;
Gillissen, G ;
Verhaagh, S ;
Custers, J ;
Zuijdgeest, D ;
Berkhout, B ;
Bakker, M ;
Quax, P ;
Goudsmit, J ;
Havenga, M .
JOURNAL OF VIROLOGY, 2004, 78 (23) :13207-13215
[20]   Identification of adenovirus (Ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (Addl1520) for treatment of liver tumors [J].
Hong, SS ;
Habib, NA ;
Franqueville, L ;
Jensen, S ;
Boulanger, PA .
JOURNAL OF VIROLOGY, 2003, 77 (19) :10366-10375